




The Haunting Question: Nevus or Melanoma?

Ürkütücü Soru: Nevüs mü? Melanom mu?

Prof. Dr. Nesimi Büyükbabani

*Istanbul University Istanbul Faculty of Medicine Pathology
Department*

İ. Ü. İstanbul Tıp Fakültesi Patoloji Anabilim Dalı



Melanocytic lesion in a female patient.


Histopathology will come first !


Other information like:

**Age, localization, clinical appearance
will be disclosed later !**

**What is the order of importance of these the factors when making a
diagnosis ?**


Can we always be consistent while reasoning in such a case ?






18046-09


136/17-18





136/19-20





136/21-22













- Symmetrical** melanocytic lesion.
- Spindle and epitheloid melanocytic cells
- Quite uniform nuclei, small nucleoli, ground glass pink cytoplasm
- Size of junctional nests quite **uniform**, **no** intraepidermal **pagetoid spread**
- Uniform **epidermal hyperplasia**, **no ulceration**
- Prominent **telangiectasias** in papillary dermis, no Kamino bodies
- Slight reactive **lymphocytic infiltration** around deep dermal vessels
- Dermal component **thickness 1.50 mm**
- No involvement of subcutaneous tissue
- No pushing border
- Maturation** in the deepest part **questionable**


What is your first impression diagnosis ?


Spitz nevus ?? Melanoma ?? or other ??

Which other missing information you want to have ??









137/06

5-6 mitosis in total were seen.

Mitotic count $<2/\text{mm}^2$


Some of them are situated at the **deep** part of the lesion.


No atypical mitotic figure seen.

What is your diagnosis now ?

Spitz nevus ?? Melanoma ?? or other ??


Which other missing information you want to have ??






HMB45

137/10



Ki67
137/11



Ki67
137/12

HMB45 positive staining in just a few junctional cells. Dermal cells negative.

Ki67 evaluation difficult.

Intermingled keratinocytes and especially inflammatory cells.


Slightly higher index in superficial part, but <10%

What is your diagnosis now ?



Spitz nevus ?? Melanoma ?? or other ??

Did you change it ?

Which other missing information you want to have ??










Which other missing information you want to have ??

Age of the patient: 74

**Clinical information: Noticed by the patient 15-20 days before removal.
Symmetrical, lightly coloured, slightly elevated lesion
on the posterior aspect of the left thigh.**

What is your final diagnosis ??



Final Diagnosis: Atypical Spitz Tumor


Management: Reexcision with 1 cm margins and SLNB

No melanocytic deposit.

PET-CT: Without any particularity.

Follow-up information:

Regularly followed. 27 months. Last visit September 2011.



Spitzoid Melanocytic Lesions

Terminology

Dichotomous classification **Spitz Nevus – Melanoma**

Spitzoid lesions → **Different from banal nevi and melanoma (CGH, mutation analysis, behavior)**

Better categorisation of Spitzoid neoplasms

- Spitz tumor without significant abnormality (**Spitz Nevi**),
- Spitz tumor with atypical features (**atypical Spitz tumor**[AST]),
some with indeterminate biological potential, and
- Malignant melanoma**

Barnhill RL. Mod Pathol. 2006 Feb;19 Suppl 2:S21-33.



Table 5 Histopathological criteria for atypical Spitz tumors

Organizational criteria

Diameter in mm (≥ 10 mm considered abnormal)

Depth in mm (involvement of subcutaneous fat considered abnormal)

Ulceration

Poor circumscription

Pagetoid melanocytosis over a large front

→ Prominent confluence of melanocytes

→ High cellular density

→ Lack of zonation and maturation

Asymmetry

Few or no dull pink (Kamino) bodies

Proliferational criteria

→ Significant mitotic rate— $> 2-6/\text{mm}^2$

→ Deep/marginal mitoses

→ Proliferation index, that is, Ki-67 expression

Between 2 and 10% (Vollmer)

$\geq 10\%$ (Kapor *et al*³⁸)

Cytological criteria

Granular vs ground glass cytoplasm

High nuclear to cytoplasmic ratios

Loss of delicate or dispersed chromatin patterns

Thickening of nuclear membranes

Hyperchromatism

Large nucleoli

Differentiation of Spitz Tumor – Melanoma

Clinical Features

Age

349 Spitz nevi cases 40% \leq 15 years old

13/217 (6%) cases in females \geq 45 years old

“... we believe that no changes should be made to a clear histopathological diagnosis of Spitz nevus or melanoma because of the patient’s age.”


Requena C et al. Am J Dermatopathol. 2009 Apr;31(2):107-16.

247 Spitz nevi 66% \geq 20 years old

21/162 (13%) cases in females \geq 40 years old

in 60% of women \geq 40 the lesion developed on the leg

Cesinaro AM et al. Am J Dermatopathol. 2005 Dec;27(6):469-75.



Differentiation of Spitz Tumor – Melanoma

Clinical Features

Age


Yale group

Spitz naevi age range **6 months-71 years**
 average age 22, median age 19

Ratio of Spitz naevi/melanoma

age	≤20 years	60:1
	20-29 years	3:2
	30-39 years	1:3
	40-49 years	1:7
	>50 years	1:60

Herreid PA, Shapiro PE. Arch Dermatol 1996; 132: 352–3.



Differentiation of Spitz Tumor – Melanoma

Immunohistochemistry

29 compound Spitz nevi

8/29 (28%) negative; 5/29 (17%) epidermal component only; 16/29 (55%), including 10 deep SNs, both the epidermal and dermal components.

10 deep SNs 8/10 upper dermis only; 2/10 some cells in deep dermis.

Stratified pattern of HMB-45 staining


Bergman R et al. Am J Dermatopathol. 1995 Dec;17(6):542-6.

p27 expression was significantly higher in Spitz nevi

Stefanaki C et al. J Am Acad Dermatol. 2007 May;56(5):815-24.

“a high level of p21 expression makes a tumor more likely to be a typical or atypical Spitz nevus than a malignant melanoma”

Kapur P et al. Mod Pathol. 2005 Feb;18(2):197-204.



Differentiation of Spitz Tumor – Melanoma

Ancillary Techniques

Molecular Pathology

Early Studies


96 spitzoid melanocytic lesions mutations in BRAF, NRAS, and HRAS
BRAF or NRAS mutations 31/36 (86%) spitzoid melanomas
0/14 Spitz nevi and 0/16 atypical Spitz nevi

HRAS mutations

4/14 (29%) Spitz nevi and 3/22 (14%) atypical Spitz nevi
0/36 spitzoid melanomas

“Spitz nevi and spitzoid melanomas are **genetically unrelated** entities.”

van Dijk MC et al. Am J Surg Pathol. 2005 Sep;29(9):1145-51.



Differentiation of Spitz Tumor – Melanoma

Ancillary Techniques

Molecular Pathology

HRAS mutation analysis


93 Spitz nevi and 77 STUMPs → **24 lesions harbored HRAS mutation.**

None of the HRAS mutated cases developed recurrences or metastases (10.5 years of follow-up).

HRAS mutations had not been reported in Spitzoid melanomas.

HRAS mutation analysis may be a useful diagnostic tool.

Blokx WA et al. Am J Surg Pathol. 2010 Oct;34(10):1436-41.



Differentiation of Spitz Tumor – Melanoma

Ancillary Techniques

Molecular Pathology

FISH

RREB1 (6p25)/MYB (6q23)/CCND1 (11q13)/CEP6 (6p11.1-q11 Alpha Satellite DNA)

38 controversial, atypical Spitzoid lesions (≥ 1 mm in thickness)

4 lymph node deposits (SLNB), 4 bulky metastases (1 death).

FISH analysis → **chromosomal alterations in 6/25 cases** (incl. the fatal case)

“FISH assay may be of help in the prognostic evaluation of atypical Spitzoid tumors. But require validation in a larger series with longer follow-up information.”

Massi D et al. J Am Acad Dermatol. 2011 May;64(5):919-35.



Conclusions

What to do in front of a “Spitzoid” melanocytic lesion?

Examination of the entire lesion → Is there **a clearcut melanoma ??**

→ Is there a **“Spitzoid tumor without atypicality” ??**

If not → Try to obtain **detailed clinical information including photographs**

→ **Careful histopathological examination**

immunohistochemistry (HMB45, Ki67),

other additional means (CGH, HRAS mutation, FISH) if available

→ **Consultation**

Risk assesement

Management

Reexcision, consideration of SLNB

Long term follow-up with regular intervals

